Oasmia Pharmaceutical has announced the appointment of Fredrik Järrsten as Chief Financial Officer reporting to Francois Martelet, Chief Executive Officer.
“We are delighted to have Fredrik joining the Oasmia team as Chief Financial Officer. His vast experience as a leader, developing businesses across the healthcare and life sciences sector, will be invaluable to Oasmia as we continue to pursue our strategy of accelerating growth, both organically and through acquisition,” says Francois Martelet, CEO of Oasmia.
Over 25 years of experience across the financial, medical technology and life sciences sectors
Järrsten has over 25 years of experience across the financial, medical technology and life sciences sectors in the Nordic region and internationally. Currently, he serves as CFO and deputy CEO at Karolinska Development, an investment company specializing in the Nordic life sciences sector. Prior to this, he was CFO and Business Development Director at Bactiguard, a Swedish medical device company which he guided through its Nasdaq Stockholm IPO. Järrsten also served as a Director of Business Development, including M&A, at Aleris, a leading Nordic healthcare provider, for over 8 years. He holds a degree in Accounting and Finance from the Stockholm School of Economics and International Business from the School of Business Adminstration, University of Michigan.
”I am excited to be joining Oasmia at this important time in the company’s development. I look forward to working alongside senior management and the Board as we look to meet Oasmia’s strategic goals,” says Fredrik Järrsten.
He will take up his position as soon as practically possible but at the latest in six months from today.
Photo of Fredrik Järrsten